Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3931843 | 0.80 | KDR (0.32) | AAK1 | |
| SCHEMBL3936369 | 0.72 | HPGDS (0.47) | — | |
| SCHEMBL3929916 | 0.72 | DYRK1B (0.40) | FYN | |
| SCHEMBL3934029 | 0.71 | DYRK1B (0.42) | — | |
| SCHEMBL3925262 | 0.71 | HSD11B1 (0.43) | — | |
| SCHEMBL3929259 | 0.69 | KDR (0.39) | — | |
| SCHEMBL1956177 | 0.66 | HTR2C (0.43) | — | |
| SCHEMBL3929172 | 0.64 | PTGER1 (0.35) | FYN | |
| SCHEMBL3928721 | 0.64 | MAPK10 (0.42) | FYN | |
| SCHEMBL3931771 | 0.63 | HTT (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-7504401-B2 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | AAK1 4049/4885FYN 1524/4885 |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | AAK1 4051/4885FYN 1515/4885 |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | NR2E3, RB1, CBR3 | AAK1 3930/4885FYN 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.